Cindy Yusing Wang, MD
Cardiovascular Disease (Cardiology) · San Jose
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 19
- 5 carriers
- Office
- 1
Offices
1 location · El Camino Health Medical Network LLC · 202 clinicians in this group
Hospitals listed: El Camino Health. That is not proof they admit you there this week.
Plans that list them
19 plans · 5 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Wang’s office at (408) 871-3400 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
19 of 19 plans
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Anthem Prime (HMO-POS) | Anthem Blue Cross Partnership Plan | Listed | Oct 3, 2026 |
| Blue Shield Inspire (HMO) | Blue Shield of California | Listed | Aug 26, 2026 |
| Central Health Classic Care Plan III (HMO) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Dual Access Plan (HMO D-SNP) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Embrace Care Plan (HMO C-SNP) | Central Health Medicare Plan | Listed, may be out of date | Sep 15, 2025 |
| Central Health Embrace Choice Plan (HMO C-SNP) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Valor Care Plan (HMO) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
California Medical Board record
Licence A136223 · Current
Licensed to practise in California · since 2015 · expires 2028-08-31 · New York Medical College.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- El Camino HealthMountain View, CAAcute Care Hospital · Government - Hospital District or Authority · Has an emergency department · Birthing-friendlyPart of El Camino Health, which runs 2 hospitalsPatients rate it 4 of 5 · 80% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.291, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.393, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0, Oct 2024 – Sep 2025
See every measure and the patient survey for El Camino Health
Behind the star rating — Deaths: 3 better, 5 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 1 better, 9 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.291 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.393 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.96 (0.12 to 1.79) · 2,340 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.02 (0.76 to 1.28) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 167.38 (125.03 to 209.73) · 96 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.6 · 68 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.1 · 185 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.8 · 200 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8.9 · 814 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 13 · 842 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.6 · 361 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.6 · 4,633 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.16 (0 to 0.34) · 11,474 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.27 (0.1 to 0.45) · 11,626 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.14 (1.39 to 4.9) · 2,814 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 2 (0.61 to 3.39) · 1,327 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.11 (0.8 to 3.43) · 2,641 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 9.39 (4.18 to 14.6) · 1,287 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 6.57 (3.47 to 9.68) · 1,308 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 2.14 (0.71 to 3.57) · 827 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.6 (0.05 to 1.15) · 9,460 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.5 · 122 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.993 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.706 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.376 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.5 · 218 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.5 · 962 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 3.8 · 200 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -17 · 922 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 18.6 · 860 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.7 · 827 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.1 (4.5 to 8.2) · 313 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 13.4 (10.6 to 16.5) · 313 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.1 · 144 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.3 · 80 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.7 · 237 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.8 (10 to 16.1) · 1,639 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.8 to 1.1) · 1,619 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,535 patients answered, 22% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 79% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 61% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 86% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 76% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 75% |
| Nurses "always" listened carefully | 76% |
| Nurses "always" treated them with courtesy and respect | 87% |
| "Always" quiet at night | 47% |
| "YES", patients would definitely recommend the hospital | 80% |
| Staff "always" explained possible side effects | 46% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
Original Medicare doctor bills
$351,678
Medicare paid this office $351,678 for 1,560 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 479 | $105,672 | $115 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 265 | $51,709 | $192 |
| Long return visit (40+ min) | 251 | $43,339 | $153 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 78 | $36,512 | $468 |
| Heart rhythm recording, analysis, interpretation and report of continous external ekg over more than 1 week up to 1 weeks | 42 | $13,934 | $290 |
See all 25 services
| Return visit (30+ min) | 479 | $105,672 | $115 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 265 | $51,709 | $192 |
| Long return visit (40+ min) | 251 | $43,339 | $153 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 78 | $36,512 | $468 |
| Heart rhythm recording, analysis, interpretation and report of continous external ekg over more than 1 week up to 1 weeks | 42 | $13,934 | $290 |
| Technetium tc-99m tetrofosmin, diagnostic, per study dose | 83 | $12,121 | $74 |
| Critical care, first 30-74 minutes | 25 | $9,894 | $177 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 65 | $9,046 | $70 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 141 | $8,345 | $59 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 67 | $7,422 | $108 |
| New patient visit (45+ min) | 49 | $6,927 | $141 |
| Heart rhythm recording, analysis, report, review, and interpretation of continous external ekg over more than 48 hours up to 7 days | 23 | $6,353 | $265 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 424 | $6,060 | $12 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 91 | $5,831 | $63 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 505 | $3,848 | $6 |
| Ct scan of blood vessels and grafts of heart with contrast | 31 | $3,767 | $102 |
| Programming of dual lead pacemaker system | 32 | $2,417 | $46 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 28 | $1,796 | $44 |
| Short return visit (20+ min) | 17 | $1,480 | $87 |
| Ultrasound of heart with probe in esophagus, with report | 12 | $1,228 | $94 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 17 | $1,226 | $68 |
| External shock to heart to regulate heart beat | 11 | $1,174 | $98 |
| Injection, regadenoson, 0.1 mg | 43 | $682 | None |
| Analysis of data from ct study of heart blood vessels to assess severity of heart artery disease, with interpretation and report | 15 | $540 | $32 |
| Blood test, clotting time | 12 | $202 | $4 |
Who their Medicare patients are
1,560 Original Medicare patients in 2024. Average age 79 · Under 65 2% · 85 and older 29% · Women 52% · Also on Medicaid 14% · Health risk score 1.55. At or below the middle of the specialty; the typical cardiology clinician is at 1.71.
Conditions among them: High blood pressure 75% · Coronary heart disease 44% · Atrial fibrillation 36% · Diabetes 35% · Heart failure 31% · Chronic kidney disease 30% · Cancer 19% · Depression 18% · COPD 15% · Dementia 14% · Stroke 14%.
The office billed $1,624,177, Medicare allowed $470,436 and paid $351,678; for 3,986 services of 63 kinds; $682 of it was for drugs given in the office and $350,995 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 1,560 | 3,986 | 79 | 1.55 | $1,624,177 | $351,678 |
| 2023 | 1,277 | 3,597 | 79 | 1.45 | $1,364,232 | $307,656 |
| 2022 | 953 | 2,552 | 78 | 1.57 | $881,460 | $205,375 |
| 2021 | 1,338 | 5,119 | 79 | 1.40 | $2,069,481 | $482,672 |
| 2020 | 1,138 | 4,412 | 79 | 1.44 | $2,155,949 | $449,312 |
| 2019 | 425 | 1,157 | 79 | 1.34 | $593,840 | $119,272 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 26 services
| Return visit (30+ min) | 373 | $78,370 | $111 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 224 | $44,588 | $197 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 86 | $40,760 | $474 |
| Long return visit (40+ min) | 126 | $26,430 | $162 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 71 | $17,474 | $107 |
| New patient visit (45+ min) | 84 | $12,183 | $145 |
| Technetium tc-99m tetrofosmin, diagnostic, per study dose | 89 | $11,910 | $67 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 60 | $9,511 | $156 |
| Heart rhythm recording, analysis, report, review, and interpretation of continous external ekg over more than 48 hours up to 7 days | 22 | $7,211 | $288 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 114 | $7,104 | $61 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 92 | $6,337 | $68 |
| Injection, regadenoson, 0.1 mg | 38 | $6,301 | None |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 329 | $4,971 | $13 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 168 | $4,660 | $21 |
| Heart rhythm recording, analysis, interpretation and report of continous external ekg over more than 1 week up to 1 weeks | 14 | $4,247 | $303 |
| Critical care, first 30-74 minutes | 12 | $3,759 | $188 |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 14 | $3,402 | $243 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 395 | $3,381 | $7 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 15 | $1,996 | $71 |
| Telephone medical discussion with physician, 21-30 minutes | 18 | $1,265 | $67 |
| Programming of dual lead pacemaker system | 13 | $858 | $34 |
| Heart rhythm review, and interpretation of continous external ekg over more than 48 hours up to 7 days | 35 | $727 | $21 |
| Ultrasound of heart blood flow, valves and chambers | 12 | $634 | $53 |
| Heart rhythm recording continous external ekg over more than 48 hours up to 7 days | 34 | $413 | $12 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 14 | $359 | $26 |
| Blood test, clotting time | 27 | $336 | $4 |
2022: 20 services
| Return visit (30+ min) | 293 | $58,805 | $115 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 63 | $30,797 | $489 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 145 | $26,654 | $181 |
| Technetium tc-99m tetrofosmin, diagnostic, per study dose | 64 | $11,302 | $88 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 45 | $9,804 | $92 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 48 | $8,834 | $180 |
| Long return visit (40+ min) | 44 | $8,034 | $167 |
| New patient visit (45+ min) | 50 | $7,260 | $145 |
| Injection, regadenoson, 0.1 mg | 32 | $6,174 | None |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 89 | $5,661 | $64 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 65 | $4,615 | $71 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 122 | $3,198 | $21 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 226 | $3,018 | $12 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 289 | $2,594 | $7 |
| Telephone medical discussion with physician, 11-20 minutes | 38 | $2,212 | $51 |
| Short return visit (20+ min) | 37 | $1,893 | $51 |
| Heart rhythm review, and interpretation of continous external ekg over more than 48 hours up to 7 days | 40 | $1,019 | $22 |
| Heart rhythm recording continous external ekg over more than 48 hours up to 7 days | 40 | $687 | $15 |
| Programming of dual lead pacemaker system | 12 | $516 | $30 |
| Blood test, clotting time | 25 | $262 | $4 |
2021: 27 services
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 236 | $123,764 | $497 |
| Return visit (30+ min) | 326 | $75,962 | $119 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 350 | $73,723 | $199 |
| Technetium tc-99m tetrofosmin, diagnostic, per study dose | 218 | $36,880 | $85 |
| Injection, regadenoson, 0.1 mg | 141 | $26,825 | None |
| Long return visit (40+ min) | 159 | $26,371 | $149 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 80 | $20,781 | $94 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 233 | $16,662 | $71 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 67 | $12,288 | $181 |
| New patient visit (45+ min) | 84 | $11,867 | $141 |
| Short return visit (20+ min) | 80 | $10,981 | $83 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 258 | $8,956 | $21 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 82 | $5,422 | $65 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 302 | $4,345 | $13 |
| Telephone medical discussion with physician, 11-20 minutes | 34 | $3,962 | $81 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 307 | $2,938 | $7 |
| Programming of dual lead pacemaker system | 32 | $2,019 | $45 |
| Ultrasound of heart with probe in esophagus, with report | 17 | $1,700 | $100 |
| External shock to heart to regulate heart beat | 11 | $1,223 | $102 |
| Blood test, clotting time | 71 | $1,107 | $4 |
| Heart rhythm review, and interpretation of continous external ekg over more than 48 hours up to 7 days | 43 | $983 | $23 |
| Heart rhythm recording continous external ekg over more than 48 hours up to 7 days | 58 | $876 | $15 |
| Hospital discharge day management, 30 minutes or less | 13 | $874 | $67 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system or implantable defibrillator system, remote up to 90 days | 13 | $509 | $25 |
| Heart rhythm review and interpretation of continous external ekg over 8-15 days | 17 | $428 | $25 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | 12 | $421 | $25 |
| Heart rhythm recording of continous external ekg over 8-15 days | 13 | $217 | $17 |
2020: 30 services
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 235 | $119,620 | $509 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 554 | $118,256 | $205 |
| Technetium tc-99m tetrofosmin, diagnostic, per study dose | 178 | $29,770 | $84 |
| Return visit (30+ min) | 192 | $28,065 | $98 |
| Injection, regadenoson, 0.1 mg | 128 | $23,986 | None |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 87 | $20,774 | $96 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 440 | $15,500 | $21 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 220 | $15,324 | $69 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 66 | $12,801 | $186 |
| Long return visit (40+ min) | 68 | $11,645 | $139 |
| New patient visit (45+ min) | 75 | $10,782 | $144 |
| Telephone medical discussion with physician, 21-30 minutes | 32 | $4,284 | $100 |
| Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | 18 | $4,157 | $231 |
| New patient visit (60+ min) | 21 | $4,137 | $197 |
| Ultrasound of heart with probe in esophagus, with report | 28 | $3,238 | $101 |
| Telephone medical discussion with physician, 11-20 minutes | 31 | $2,818 | $70 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 119 | $1,992 | $16 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 29 | $1,984 | $68 |
| Short return visit (20+ min) | 23 | $1,755 | $70 |
| External shock to heart to regulate heart beat | 14 | $1,747 | $103 |
| Blood test, clotting time | 89 | $1,574 | $4 |
| External ekg recording for more than 48 hours up to 21 days | 45 | $1,350 | $28 |
| Programming of dual lead pacemaker system | 19 | $1,300 | $57 |
| Review and interpretation of external ekg recording for more than 48 hours up to 21 days | 45 | $1,180 | $25 |
| Hospital discharge day management, 30 minutes or less | 14 | $954 | $68 |
| Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | 11 | $888 | $81 |
| Ultrasound of heart blood flow, valves and chambers | 16 | $671 | $42 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 58 | $454 | $7 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 17 | $377 | $22 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 11 | $122 | $11 |
2019: 14 services
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 198 | $41,192 | $208 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 53 | $26,744 | $505 |
| Return visit (30+ min) | 59 | $6,883 | $101 |
| Technetium tc-99m tetrofosmin, diagnostic, per study dose | 35 | $6,097 | $87 |
| New patient visit (45+ min) | 37 | $5,508 | $149 |
| Injection, regadenoson, 0.1 mg | 27 | $5,016 | None |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 182 | $4,886 | $23 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 26 | $4,488 | $65 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 36 | $2,504 | $70 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 11 | $1,990 | $181 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 13 | $1,952 | $93 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 11 | $1,341 | $122 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 51 | $871 | $16 |
| Blood test, clotting time | 58 | $411 | $4 |
Medicaid work
$1,640 in 2024
Medicaid paid $1,640 for 334 billed services this clinician did in 2024, up to 130 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 322 | $1,515 |
| Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography | 12 | $124 |
| 2024 | 334 | 2 | 130 | $1,640 |
| 2023 | 265 | 1 | 105 | $1,111 |
| 2022 | 207 | 1 | 90 | $1,072 |
| 2021 | 195 | 1 | 85 | $770 |
| 2020 | 68 | 1 | 27 | $328 |
See the largest Medicaid services in earlier years
2023
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 265 | $1,111 |
2022
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 207 | $1,072 |
2021
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 195 | $770 |
2020
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 68 | $328 |
Drugs they prescribed that Part D paid
$893,139
Pharmacies billed $893,139 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 4,019) in 2024. At or below the middle of the specialty; the typical cardiology clinician is at 0%.
3,296 generic and 723 brand-name prescriptions · $893,139 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Eliquis | 259 | $346,243 | $1,337 |
| Entresto | 153 | $179,244 | $1,172 |
| Xarelto | 105 | $146,235 | $1,393 |
| Jardiance | 32 | $46,404 | $1,450 |
| Repatha Sureclick | 35 | $38,990 | $1,114 |
See all 51 drugs
| Eliquis | 259 | $346,243 | $1,337 |
| Entresto | 153 | $179,244 | $1,172 |
| Xarelto | 105 | $146,235 | $1,393 |
| Jardiance | 32 | $46,404 | $1,450 |
| Repatha Sureclick | 35 | $38,990 | $1,114 |
| Wegovy | 11 | $16,228 | $1,475 |
| Farxiga | 11 | $12,267 | $1,115 |
| Praluent | 13 | $9,676 | $744 |
| Metoprolol | 345 | $6,022 | $17 |
| Atorvastatin | 398 | $5,249 | $13 |
| Rosuvastatin | 221 | $3,966 | $18 |
| Ezetimibe | 69 | $3,523 | $51 |
| Potassium Chloride | 99 | $2,543 | $26 |
| Flecainide Acetate | 61 | $2,491 | $41 |
| Carvedilol | 198 | $2,304 | $12 |
| Amiodarone | 49 | $2,239 | $46 |
| Bumetanide | 44 | $1,966 | $45 |
| Lisinopril | 142 | $1,921 | $14 |
| Diltiazem 24hr Er (Cd) | 45 | $1,900 | $42 |
| Losartan | 152 | $1,787 | $12 |
| Amlodipine Besylate | 237 | $1,724 | $7 |
| Spironolactone | 81 | $1,138 | $14 |
| Valsartan | 47 | $1,069 | $23 |
| Torsemide | 51 | $1,054 | $21 |
| Furosemide | 141 | $980 | $7 |
| Simvastatin | 67 | $903 | $13 |
| Isosorbide Mononitrate Er | 62 | $833 | $13 |
| Nebivolol | 19 | $798 | $42 |
| Valsartan-Hydrochlorothiazide | 12 | $684 | $57 |
| Metoprolol | 94 | $608 | $6 |
| Ramipril | 42 | $583 | $14 |
| Diltiazem 24hr Er (Xr) | 11 | $551 | $50 |
| Clopidogrel | 44 | $540 | $12 |
| Benazepril | 32 | $525 | $16 |
| Losartan-Hydrochlorothiazide | 43 | $500 | $12 |
| Pravastatin | 46 | $496 | $11 |
| Telmisartan | 12 | $340 | $28 |
| Chlorthalidone | 15 | $331 | $22 |
| Atenolol | 34 | $327 | $10 |
| Nitroglycerin | 44 | $290 | $7 |
| Irbesartan | 22 | $287 | $13 |
| Warfarin | 19 | $282 | $15 |
| Sotalol | 14 | $275 | $20 |
| Allopurinol | 13 | $211 | $16 |
| Nifedipine Er | 12 | $197 | $16 |
| Verapamil Er | 12 | $196 | $16 |
| Bisoprolol | 15 | $179 | $12 |
| Triamterene-Hydrochlorothiazid | 14 | $169 | $12 |
| Hydrochlorothiazide | 43 | $150 | $3 |
| Amlodipine Besylate-Benazepril | 15 | $142 | $9 |
| Hydralazine | 11 | $133 | $12 |
Year by year
| 2024 | 4,019 | 635 | 0% (0) | 18% | $893,139 |
| 2023 | 3,121 | 469 | None | 17% | $708,742 |
| 2022 | 2,552 | 365 | 0% (0) | 17% | $522,474 |
| 2021 | 2,320 | 402 | None | 16% | $352,851 |
| 2020 | 1,083 | 244 | 0% (0) | 22% | $147,155 |
| 2019 | 168 | 71 | 0% (0) | 21% | $16,038 |
| 2018 | 84 | 23 | 0% (0) | 20% | $7,882 |
| 2017 | 148 | 59 | None | 23% | $11,004 |
| 2016 | 122 | 40 | None | None | $9,051 |
| 2015 | 17 | None | None | None | $970 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 43 drugs
| Eliquis | 208 | $291,734 | $1,403 |
| Entresto | 98 | $145,101 | $1,481 |
| Xarelto | 86 | $120,144 | $1,397 |
| Repatha Sureclick | 14 | $22,444 | $1,603 |
| Repatha Pushtronex | 11 | $13,353 | $1,214 |
| Metoprolol | 208 | $4,852 | $23 |
| Flecainide Acetate | 54 | $4,722 | $87 |
| Potassium Chloride | 102 | $4,102 | $40 |
| Atorvastatin | 307 | $3,892 | $13 |
| Carvedilol | 227 | $3,653 | $16 |
| Bumetanide | 32 | $2,777 | $87 |
| Nebivolol | 12 | $2,491 | $208 |
| Ezetimibe | 52 | $2,300 | $44 |
| Rosuvastatin | 105 | $2,142 | $20 |
| Amlodipine Besylate | 206 | $1,916 | $9 |
| Valsartan | 27 | $1,487 | $55 |
| Losartan | 92 | $1,367 | $15 |
| Torsemide | 34 | $1,348 | $40 |
| Diltiazem 24hr Er (Cd) | 25 | $1,316 | $53 |
| Amiodarone | 37 | $1,283 | $35 |
| Isosorbide Mononitrate Er | 58 | $1,153 | $20 |
| Diltiazem | 13 | $1,152 | $89 |
| Furosemide | 144 | $1,016 | $7 |
| Lisinopril | 109 | $916 | $8 |
| Clopidogrel | 45 | $876 | $19 |
| Simvastatin | 62 | $785 | $13 |
| Metoprolol | 74 | $739 | $10 |
| Diltiazem 24hr Er (Xr) | 12 | $691 | $58 |
| Digoxin | 19 | $684 | $36 |
| Spironolactone | 52 | $645 | $12 |
| Hydralazine | 18 | $572 | $32 |
| Ramipril | 38 | $537 | $14 |
| Hydrochlorothiazide | 61 | $515 | $8 |
| Verapamil Er | 12 | $501 | $42 |
| Nitroglycerin | 46 | $457 | $10 |
| Losartan-Hydrochlorothiazide | 23 | $424 | $18 |
| Atenolol | 21 | $405 | $19 |
| Benazepril | 21 | $365 | $17 |
| Bisoprolol | 11 | $313 | $28 |
| Pravastatin | 26 | $285 | $11 |
| Irbesartan | 19 | $200 | $11 |
| Warfarin | 16 | $148 | $9 |
| Lisinopril-Hydrochlorothiazide | 11 | $33 | $3 |
2022: 40 drugs
| Eliquis | 169 | $230,790 | $1,366 |
| Xarelto | 70 | $94,259 | $1,347 |
| Entresto | 70 | $92,169 | $1,317 |
| Repatha Sureclick | 14 | $18,528 | $1,323 |
| Metoprolol | 178 | $3,742 | $21 |
| Rosuvastatin | 92 | $3,074 | $33 |
| Atorvastatin | 225 | $2,884 | $13 |
| Flecainide Acetate | 25 | $2,501 | $100 |
| Potassium Chloride | 62 | $2,452 | $40 |
| Carvedilol | 154 | $2,366 | $15 |
| Ezetimibe | 32 | $2,330 | $73 |
| Toprol Xl | 11 | $1,697 | $154 |
| Amlodipine Besylate | 169 | $1,404 | $8 |
| Isosorbide Mononitrate Er | 51 | $1,309 | $26 |
| Torsemide | 47 | $1,286 | $27 |
| Valsartan | 23 | $1,269 | $55 |
| Bumetanide | 17 | $1,167 | $69 |
| Clopidogrel | 49 | $1,078 | $22 |
| Losartan | 92 | $970 | $11 |
| Diltiazem | 13 | $969 | $75 |
| Valsartan-Hydrochlorothiazide | 13 | $882 | $68 |
| Lisinopril | 90 | $812 | $9 |
| Ramipril | 56 | $786 | $14 |
| Amiodarone | 23 | $747 | $32 |
| Diltiazem 24hr Er (Cd) | 24 | $746 | $31 |
| Metoprolol | 61 | $746 | $12 |
| Furosemide | 115 | $717 | $6 |
| Digoxin | 13 | $564 | $43 |
| Nitroglycerin | 21 | $535 | $25 |
| Spironolactone | 45 | $499 | $11 |
| Benazepril | 27 | $491 | $18 |
| Warfarin | 30 | $468 | $16 |
| Simvastatin | 48 | $463 | $10 |
| Losartan-Hydrochlorothiazide | 14 | $420 | $30 |
| Hydralazine | 13 | $382 | $29 |
| Irbesartan | 22 | $377 | $17 |
| Pravastatin | 25 | $371 | $15 |
| Atenolol | 16 | $320 | $20 |
| Hydrochlorothiazide | 55 | $300 | $5 |
| Lisinopril-Hydrochlorothiazide | 13 | $37 | $3 |
2021: 42 drugs
| Eliquis | 125 | $148,320 | $1,187 |
| Entresto | 54 | $55,618 | $1,030 |
| Xarelto | 44 | $51,363 | $1,167 |
| Repatha Sureclick | 13 | $12,436 | $957 |
| Metoprolol | 148 | $4,173 | $28 |
| Ezetimibe | 40 | $3,817 | $95 |
| Valsartan | 51 | $3,697 | $72 |
| Atorvastatin | 194 | $2,974 | $15 |
| Flecainide Acetate | 26 | $2,609 | $100 |
| Carvedilol | 166 | $2,355 | $14 |
| Toprol Xl | 13 | $1,945 | $150 |
| Dilt-Xr | 22 | $1,821 | $83 |
| Rosuvastatin | 56 | $1,812 | $32 |
| Diltiazem 24hr Er (Cd) | 25 | $1,734 | $69 |
| Isosorbide Mononitrate Er | 54 | $1,677 | $31 |
| Amlodipine Besylate | 132 | $1,520 | $12 |
| Potassium Chloride | 45 | $1,460 | $32 |
| Losartan | 92 | $1,417 | $15 |
| Diltiazem 24hr Er | 22 | $1,031 | $47 |
| Nitroglycerin | 43 | $1,013 | $24 |
| Clopidogrel | 50 | $950 | $19 |
| Torsemide | 23 | $919 | $40 |
| Valsartan-Hydrochlorothiazide | 16 | $902 | $56 |
| Bumetanide | 12 | $758 | $63 |
| Lisinopril | 75 | $696 | $9 |
| Ramipril | 41 | $693 | $17 |
| Metoprolol | 60 | $684 | $11 |
| Furosemide | 104 | $680 | $7 |
| Nifedipine Er | 15 | $669 | $45 |
| Diltiazem | 11 | $623 | $57 |
| Amiodarone | 15 | $536 | $36 |
| Spironolactone | 39 | $529 | $14 |
| Pravastatin | 25 | $529 | $21 |
| Digoxin | 16 | $529 | $33 |
| Simvastatin | 45 | $498 | $11 |
| Warfarin | 25 | $432 | $17 |
| Hydralazine | 15 | $405 | $27 |
| Losartan-Hydrochlorothiazide | 17 | $386 | $23 |
| Benazepril | 24 | $373 | $16 |
| Hydrochlorothiazide | 54 | $313 | $6 |
| Atenolol | 29 | $251 | $9 |
| Irbesartan | 14 | $205 | $15 |
2020: 25 drugs
| Eliquis | 100 | $80,869 | $809 |
| Entresto | 30 | $27,202 | $907 |
| Xarelto | 16 | $10,320 | $645 |
| Metoprolol | 94 | $1,968 | $21 |
| Flecainide Acetate | 16 | $1,683 | $105 |
| Atorvastatin | 74 | $1,597 | $22 |
| Isosorbide Mononitrate Er | 46 | $1,428 | $31 |
| Potassium Chloride | 34 | $1,001 | $29 |
| Carvedilol | 79 | $971 | $12 |
| Diltiazem 24hr Er (Cd) | 23 | $922 | $40 |
| Digoxin | 11 | $679 | $62 |
| Rosuvastatin | 23 | $619 | $27 |
| Hydralazine | 21 | $603 | $29 |
| Metoprolol | 41 | $539 | $13 |
| Nitroglycerin | 19 | $487 | $26 |
| Furosemide | 72 | $424 | $6 |
| Lisinopril | 43 | $354 | $8 |
| Pravastatin | 18 | $349 | $19 |
| Amlodipine Besylate | 49 | $327 | $7 |
| Simvastatin | 25 | $321 | $13 |
| Clopidogrel | 17 | $248 | $15 |
| Losartan | 25 | $234 | $9 |
| Atenolol | 23 | $196 | $9 |
| Hydrochlorothiazide | 20 | $156 | $8 |
| Spironolactone | 12 | $128 | $11 |
2019: 3 drugs
| Eliquis | 12 | $4,374 | $364 |
| Atorvastatin | 15 | $261 | $17 |
| Metoprolol | 20 | $80 | $4 |
2017: 2 drugs
| Atorvastatin | 17 | $238 | $14 |
| Amlodipine Besylate | 13 | $77 | $6 |
2016: 2 drugs
| Atorvastatin | 13 | $183 | $14 |
| Amlodipine Besylate | 14 | $108 | $8 |
Money from drug and device companies
$1,029 in 2025
| 2025 | 12 | 28 | None | $1,029 |
| 2024 | 11 | 26 | None | $555 |
| 2023 | 10 | 25 | None | $633 |
| 2022 | 4 | 7 | None | $141 |
| 2021 | 9 | 24 | None | $662 |
| 2020 | 7 | 10 | None | $288 |
| 2019 | 4 | 8 | $1,500 | $1,736 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Medtronic | Aurora Ev-Icd Mri Surescan | $254 | 3 payments
|
| Biosense Webster | Carto 3 | $147 | 1 payment
|
| Boehringer Ingelheim Pharmaceuticals | Jardiance | $112 | 5 payments
|
| Novartis Pharmaceuticals | Leqvio | $100 | 3 payments
|
| Alnylam Pharmaceuticals | Amvuttra | $95 | 3 payments
|
| Pfizer | Eliquis | $76 | 3 payments
|
See all 27 published payments
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-12-29 | Jardiance | $25 |
| Alnylam Pharmaceuticals | Meals · 2025-12-23 | Amvuttra | $27 |
| Biosense Webster | Meals · 2025-12-12 | Carto 3 | $147 |
| Medtronic | Meals · 2025-12-12 | Aurora Ev-Icd Mri Surescan | $113 |
| Boston Scientific | Meals · 2025-12-09 | Watchman Flx | $26 |
| Esperion Therapeutics | Meals · 2025-12-04 | Nexletol | $23 |
| Alnylam Pharmaceuticals | Meals · 2025-11-17 | Amvuttra | $33 |
| Abbott Laboratories | Meals · 2025-11-11 | Amplatzer Amulet | $23 |
| Novartis Pharmaceuticals | Meals · 2025-11-04 | Leqvio | $30 |
| Alnylam Pharmaceuticals | Meals · 2025-10-16 | Amvuttra | $35 |
| Medtronic | Meals · 2025-10-14 | Aurora Ev-Icd Mri Surescan | $58 |
| Amgen | Meals · 2025-10-07 | Repatha | $31 |
| Medtronic | Meals · 2025-10-01 | Omniasecure Mri Surescan | $82 |
| Pfizer | Meals · 2025-09-30 | Eliquis | $28 |
| Amgen | Meals · 2025-09-29 | Repatha | $31 |
| Novartis Pharmaceuticals | Meals · 2025-09-25 | Leqvio | $35 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-09-23 | Jardiance | $17 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-08-19 | Jardiance | $26 |
| Edwards Lifesciences | Meals · 2025-08-12 | Sapien 3 Ultra Resilia | $48 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-08-05 | Eliquis | $19 |
| Edwards Lifesciences | Meals · 2025-06-27 | Edwards Sapien 3 Ultra Transcatheter Heart Valve | $22 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-06-24 | Jardiance | $19 |
| Pfizer | Meals · 2025-06-17 | Eliquis | $24 |
| Novartis Pharmaceuticals | Meals · 2025-05-20 | Leqvio | $35 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-05-19 | Eliquis | $24 |
| Pfizer | Meals · 2025-04-15 | Eliquis | $23 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-04-14 | Jardiance | $24 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $555
| Novartis Pharmaceuticals | Leqvio | $168 | 7 payments
|
| Amgen | Repatha | $134 | 7 payments
|
| Pfizer | Eliquis | $65 | 3 payments
|
| Boston Scientific | Watchman Flx | $45 | 2 payments
|
| Esperion Therapeutics | Nexletol | $28 | 1 payment
|
| Edwards Lifesciences | Edwards Sapien 3 Ultra Transcatheter Heart Valve | $21 | 1 payment
|
| Merck Sharp & Dohme | Verquvo | $21 | 1 payment
|
| Boehringer Ingelheim Pharmaceuticals | Jardiance | $19 | 1 payment
|
| Janssen Pharmaceuticals | Xarelto | $18 | 1 payment
|
| Heartflow | Ffrct | $17 | 1 payment
|
| Kiniksa Pharmaceuticals International plc | Arcalyst | $16 | 1 payment
|
2023: $633
| Gilead Sciences | Veklury | $122 | 1 payment
|
| Pfizer | Eliquis | $98 | 4 payments
|
| Alnylam Pharmaceuticals | Onpattro | $76 | 3 payments
|
| Novartis Pharmaceuticals | Entresto | $66 | 3 payments
|
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Lifevest | $63 | 4 payments
|
| Janssen Pharmaceuticals | Xarelto | $60 | 3 payments
|
| Merck Sharp & Dohme | Verquvo | $49 | 2 payments
|
| AstraZeneca Pharmaceuticals LP | Farxiga | $41 | 2 payments
|
| Amgen | Repatha | $38 | 2 payments
|
| Boehringer Ingelheim Pharmaceuticals | Jardiance | $19 | 1 payment
|
2022: $141
| Pfizer | Eliquis | $85 | 4 payments
|
| Sanofi-Aventis U.S. | Multaq | $23 | 1 payment
|
| Novartis Pharmaceuticals | Entresto | $18 | 1 payment
|
| Novo Nordisk | Ozempic | $16 | 1 payment
|
2021: $662
| Novo Nordisk | Ozempic | $228 | 8 payments
|
| Abbott Laboratories | Mitraclip System | $185 | 3 payments
|
| Esperion Therapeutics | Nexletol | $95 | 4 payments
|
| AstraZeneca Pharmaceuticals LP | Brilinta | $41 | 3 payments
|
| Janssen Pharmaceuticals | Xarelto | $28 | 2 payments
|
| Amarin Pharma | Vascepa | $23 | 1 payment
|
| Kiniksa Pharmaceuticals | None | $23 | 1 payment
|
| Novartis Pharmaceuticals | Entresto | $22 | 1 payment
|
| Sanofi-Aventis U.S. | Multaq | $17 | 1 payment
|
2020: $288
| Abbott Laboratories | Mitra Clip System | $124 | 2 payments
|
| Astellas Pharma US | Lexiscan | $47 | 2 payments
|
| Novartis Pharmaceuticals | Entresto | $34 | 2 payments
|
| Esperion Therapeutics | Nexletol | $24 | 1 payment
|
| Sanofi-Aventis U.S. | Multaq | $23 | 1 payment
|
| Amgen | Corlanor | $20 | 1 payment
|
| Kowa Pharmaceuticals America | Livalo | $16 | 1 payment
|
2019: $1,736
| Abbott Laboratories | Mitra Clip System | $1,660 | 4 payments
|
| AstraZeneca Pharmaceuticals LP | Brilinta | $30 | 2 payments
|
| Novartis Pharmaceuticals | Entresto | $24 | 1 payment
|
| Astellas Pharma US | Lexiscan | $21 | 1 payment
|
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 83.6 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1982966214
- Licence
- CA A136223California A136223: Current · expires 2028-08-31
- Trained
- New York Medical College, 2012
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Cardiology (207RC0000X)
- Mailing address
- 2490 Hospital Dr Ste 311, Mountain View, CA, 94040
- NPI first listed
- 2012-06-12
- NPI last updated
- 2020-12-04
- NPI record certified
- 2020-12-04
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 111 E 210th St, Bronx, NY, 10467 · 625 Lincoln Ave, San Jose, CA, 95126